faropenem medoxomil
Trade name: Fropenem
Small moleculeexperimental
Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. It is available for oral use. — Wikipedia
Clinical trial activity
7 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2005 (NCT00255983)
Timeline
Indications
Mechanism of action
- Penicillin-binding protein 1INHIBITOR
pbp1 inhibitor
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C([C@H]3CCCO3)S[C@H]12- Mol. weight
- 285.32 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL556262 ↗
- WikipediaFaropenem ↗
- ChEMBLCHEMBL431753 ↗
- ChEMBLCHEMBL1257070 ↗
Also known as
- (5r,6s)-6-(r)-1-hydroxyethyl-7-oxo-3-(r)-2-tetrahydrofuryl-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate
- a0026
- a0026
- a0026
- bay566854
- bay 566854
- bay 566854
- bay 56-6854
- bay 56-6854
- bay-566854
- bay-56-6854
- bay56-6854
- faropenem
- faropenem
- faropenem
- faropenem
- faropenem
- faropenem
- faropenem
- faropenem daloxate
- faropenem daloxate
- faropenem daloxate
- faropenem daloxate
- faropenem medoxil
- faropenem medoxil
- faropenem medoxil
- faropenem medoxil
- faropenem medoxil
- faropenem medoxil
- faropenem medoxomil
- faropenem medoxomil
- faropenem medoxomil
- faropenem medoxomil
- faropenem medoxomil
- faropenem medoxomil
- faropenem sodium
- faropenem sodium hydrate
- faropenem sodium hydrate
- faropenem sodium hydrate
- faropenem sodium hydrate
- fropenem
- fropenem
- fropenem
- fropenem
- sun208
- sun 208
- sun-208
- sun-208
- sun-208
- sun a0026
- sun-a0026
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02381470 | Phase 2 | Jul 1, 2017 | National University of Singapore |
| NCT02393586 | Phase 1 | Feb 1, 2015 | National University of Singapore |
| NCT02349841 | Phase 2 | Sep 1, 2014 | GlaxoSmithKline, Research Center Borstel, Task Foundation NPC, University Eduardo Mondlane, University of Barcelona |
| NCT01937832 | Phase 3 | Oct 1, 2013 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT01886053 | Phase 2 | Apr 1, 2011 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT00276042 | Phase 2 | Jan 1, 2006 | Replidyne |
| NCT00255983 | Phase 3 | Dec 1, 2005 | INC Research, Replidyne |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 2 | 2 | 2 | 2011 |
| National University of Singapore | Academic/Hospital | 2 | 2 | 2 | 2015 |
| Replidyne | For profit | 2 | 2 | 2 | 2005 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2014 |
| INC Research | For profit | 1 | 0 | 1 | 2005 |
| Research Center Borstel | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Task Foundation NPC | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University Eduardo Mondlane | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2014 |
9 organizations
Page 1 / 1